#TranscendentHealth: A Text Messaging Pregnancy Prevention Program for Transgender Boys (THPP)
#TranscendentHealth - Adapting an LGB+ Inclusive Teen Pregnancy Prevention Program for Transgender Boys
Transgender and gender-diverse young people who were assigned female at birth (AFAB), including transgender boys, nonbinary youth, and others, face real sexual health disparities. Existing pregnancy and HIV prevention programs are designed for cisgender girls and do not meet the needs of AFAB trans youth, leaving this group without programs that speak to their lives.
#TranscendentHealth is a text messaging sexual health program developed specifically for AFAB transgender and gender-diverse youth ages 14 to 18. It builds on Girl2Girl, a program shown to improve sexual health behaviors in LGB+ cisgender girls, and updates the content to reflect the identities, relationships, and health needs of AFAB trans youth.
The study has two parts. In the first part, AFAB trans youth help shape the program through focus groups, Content Advisory Teams (youth review panels that give feedback on program messages), and a small pilot test. In the second part, a national randomized controlled trial enrolls 467 AFAB transgender youth ages 14 to 18 across the United States. Participants are randomly assigned to receive either #TranscendentHealth or a general sexual health text messaging program. Both programs are delivered entirely by text message over 5 months, with no in-person visits required. Youth complete short online surveys at the start of the program, at program end (5 months), and at 3 and 6 months after the program ends.
The study's main goals are to determine whether #TranscendentHealth improves rates of condom-protected sex, use of other birth control methods (such as the pill, shot, or IUD), and HIV/STI testing. Secondary goals include reducing unintended pregnancy, increasing PrEP uptake among eligible participants, and improving intentions to use sexual health services.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
Background
AFAB transgender and gender-diverse youth experience substantial sexual health disparities yet are largely absent from evidence-based prevention programs. Pilot data from an earlier cohort recruited by Dr. Ybarra show that, compared with cisgender girls, AFAB trans youth are less likely to use barrier protection at last sex (p < 0.5) and at least as likely to experience adolescent pregnancy. Programs designed for cisgender girls do not address the social stressors these youth face (including discrimination, gender dysphoria, and rejection) and do not affirm their gender identities. As a result, these programs have limited uptake and effectiveness in this population.
Intervention
#TranscendentHealth adapted Girl2Girl, an evidence-based text messaging sexual health program, for AFAB trans youth. The resulting program addresses condom use, birth control options, HIV/STI testing, PrEP, gender-affirming care, dysphoria, and relationships as experienced by AFAB trans youth. The control arm delivers a universal (not gender-tailored) sexual health text messaging program with a comparable number of messages.
Study Design
National RCT (Aim 2):
A total of 467 AFAB trans youth ages 14-18 are recruited nationally through social media (Instagram and Facebook) and randomized 1:1 to intervention or control, stratified by gender (transgender boy vs. nonbinary) and sexual experience at baseline. A permuted block randomization procedure is used. All study procedures are conducted remotely: online screener, telephone enrollment, text messaging program, and online surveys. No in-person contact is required.
Participants complete assessments at baseline, program end (month 5), 3 months after program end, and 6 months after program end. Participants receive graduated incentives.
Recruitment targets are set to ensure diversity: at least 25% Hispanic, 28% multiracial, 15% Black/African American, 30% from low-income households, and approximately equal representation across urban, suburban, and rural settings. Approximately 40% of the RCT sample will be sexually inexperienced at baseline.
Tipo de estudio
Inscripción (Estimado)
Fase
- No aplica
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Michele Ybarra, PhD
- Número de teléfono: 801 877-302-6858
- Correo electrónico: michele@innovativepublichealth.org
Ubicaciones de estudio
-
-
California
-
San Clemente, California, Estados Unidos, 92672
- Center for Innovative Public Health Research (CiPHR)
-
Contacto:
- Michele Ybarra, PhD
- Número de teléfono: 801 877-302-6858
- Correo electrónico: michele@innovativepublichealth.org
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
- Niño
- Adulto
Acepta Voluntarios Saludables
Descripción
Inclusion Criteria:
- Assigned female sex at birth
- Does not have an exclusively cisgender gender identity (e.g., identifies as transgender boy, nonbinary, gender fluid, or unsure of gender identity)
- Age 14 to 18 years and has not yet graduated from high school
- Exclusive owner of a cell phone with an unlimited text messaging plan
- Has access to the Internet to complete online surveys
- Plans to keep the same cell phone number for at least the next 6 months
- Able to provide informed assent (ages 14-17) or consent (age 18), including the capacity to do so
- Has not participated in a prior #TranscendentHealth study activity and does not know anyone currently enrolled in the study
Exclusion Criteria:
- Has graduated from high school
- Has participated in a prior #TranscendentHealth study activity (focus groups, Content Advisory Teams, or beta test)
- Knows another person currently enrolled in the study
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Prevención
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Único
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: #TranscendentHealth
Participants receive a gender-tailored text messaging sexual health program over 5 months.
Program content addresses condom use, birth control options, HIV/STI testing, PrEP, gender-affirming care, sexual relationships, gender dysphoria, and social stressors relevant to AFAB transgender youth.
The program includes a Text Buddy feature for peer-to-peer support with a matched participant, and interactive achievement Badges.
|
A 5-month text messaging sexual health program for AFAB transgender and gender-diverse youth ages 14-18, adapted from the Girl2Girl program.
Content is gender-inclusive and addresses sexual health protective behaviors, gender-affirming care, relationships, and social stressors specific to AFAB trans youth.
Delivered entirely via text message; no in-person contact is required.
|
|
Comparador activo: Universal Sexual Health Program
Participants receive a universal (non-gender-tailored) sexual health text messaging program over the same 5-month period.
The program delivers a comparable number of messages covering general adolescent sexual health education that is not tailored by gender identity.
This arm does not include the Text Buddy peer-support feature.
|
5-month general (non-gender-tailored) text messaging sexual health program covering contraception, STI testing, and healthy relationships - same duration and message volume as Arm 1, no Text Buddy feature
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Rate of Condom-Protected Sex
Periodo de tiempo: Month 5 (program end), 3 months post-program end, 6 months post-program end
|
The number of sex acts in the past 90 days divided by the number of sex acts in which a condom was used, assessed separately for penile-vaginal sex, penile-anal sex, sex with a sex toy and vagina, and sex with a sex toy and anus.
|
Month 5 (program end), 3 months post-program end, 6 months post-program end
|
|
% of Participants who Report Use of Birth Control Other Than Condoms
Periodo de tiempo: Month 5 (program end), 3 months post-program end, 6 months post-program end
|
The number of youth who report using any other type of birth control (i.e., oral contraceptive pill, injectable contraceptive (Depo-Provera), vaginal ring (NuvaRing), transdermal patch (Xulane), intrauterine device (IUD, e.g., Paragard), or subdermal implant (e.g., Implanon)) divided by the number of youth in the cohort.
|
Month 5 (program end), 3 months post-program end, 6 months post-program end
|
|
Rate of HIV and STI Testing
Periodo de tiempo: Month 5 (program end), 3 months post-program end, 6 months post-program end
|
The percent of participants who report being tested for HIV, and being tested for STIs other than HIV, since the last survey.
|
Month 5 (program end), 3 months post-program end, 6 months post-program end
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
% of Participants who Report an Unintended Pregnancy
Periodo de tiempo: Month 5 (program end), 3 months post-program end, 6 months post-program end
|
The number of youth who report an unintended pregnancy divided by the number of youth in the cohort.
Assessed since the last survey (follow-up assessments) and ever (baseline).
|
Month 5 (program end), 3 months post-program end, 6 months post-program end
|
|
Rate of PrEP Use
Periodo de tiempo: Month 5 (program end), 3 months post-program end, 6 months post-program end
|
Among participants who meet clinical criteria indicating PrEP use (based on reported sexual behaviors), this will be the number of youth who report having used pre-exposure prophylaxis (PrEP) divided by the total number of youth who are eligible for PrEP.
|
Month 5 (program end), 3 months post-program end, 6 months post-program end
|
|
Relative Magnitude of Sexual Health Behavioral Intentions
Periodo de tiempo: Month 5 (program end), 3 months post-program end, 6 months post-program end
|
Using scales adapted for this intervention, continuous measures will be created by summing the responses to 5-point Likert scale items that reflect: Intentions to use condoms, initiate birth control, get tested for HIV/STIs, and discuss PrEP with a healthcare provider.
Both sexually experienced and inexperienced participants will provide responses to these scales.
|
Month 5 (program end), 3 months post-program end, 6 months post-program end
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Publicaciones y enlaces útiles
Publicaciones Generales
- Wang-Schweig M, Kviz FJ, Altfeld SJ, Miller AM, Miller BA. Building a conceptual framework to culturally adapt health promotion and prevention programs at the deep structural level. Health Promot Pract. 2014 Jul;15(4):575-84. doi: 10.1177/1524839913518176. Epub 2014 Jan 6.
- Ybarra ML, DuBois LZ, Saewyc E. Sexual Health of US Transgender Boys, Nonbinary Youth, and Cisgender Girls. JAMA Pediatr. 2025 May 12;179(7):773-80. doi: 10.1001/jamapediatrics.2025.0676. Online ahead of print.
- Ybarra ML, Liu W, Prescott TL, Phillips G 2nd, Mustanski B. The Effect of a Text Messaging Based HIV Prevention Program on Sexual Minority Male Youths: A National Evaluation of Information, Motivation and Behavioral Skills in a Randomized Controlled Trial of Guy2Guy. AIDS Behav. 2018 Oct;22(10):3335-3344. doi: 10.1007/s10461-018-2118-1.
- Ybarra M, Rosario M, Saewyc E, Goodenow C, Dunsiger S. One-Year Follow-up After a Pregnancy Prevention Intervention for LGB+ Teens: An RCT. Pediatrics. 2023 Apr 1;151(4):e2022059172. doi: 10.1542/peds.2022-059172.
- Ybarra M, Goodenow C, Rosario M, Saewyc E, Prescott T. An mHealth Intervention for Pregnancy Prevention for LGB Teens: An RCT. Pediatrics. 2021 Mar;147(3):e2020013607. doi: 10.1542/peds.2020-013607. Epub 2021 Feb 10.
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Estimado)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
Términos MeSH relevantes adicionales
- Infecciones transmitidas por la sangre
- Enfermedades urogenitales
- Enfermedades Genitales
- Procesos Patológicos
- Atributos de la enfermedad
- Enfermedades del sistema inmunológico
- Infecciones
- Infecciones por virus de ARN
- Enfermedades virales
- Enfermedades contagiosas
- Enfermedades De Transmisión Sexual Virales
- Infecciones por lentivirus
- Infecciones por retroviridae
- Síndromes de deficiencia inmunológica
- Condiciones Patológicas, Signos y Síntomas
- Comportamiento
- Infecciones por VIH
- Enfermedades de transmisión sexual
- Comportamiento Sexual
Otros números de identificación del estudio
- R01NR020846 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre Infección por VIH
-
Icahn School of Medicine at Mount SinaiClearPoint NeuroReclutamientoHemorragia Intraventricular (HIV)Estados Unidos
-
Yale UniversityTerminadoPrecocidad | Recién nacidos de muy bajo peso al nacer | Hemorragia Intraventricular (HIV) | Sangrado en el cerebroEstados Unidos
-
China Medical University HospitalDesconocidoDisplasia broncopulmonar | Bebés extremadamente prematuros | TLP grave que las terapias convencionales han fallado | Sin anomalías congénitas graves | no Hiv Severa Ni FPV QuísticaTaiwán